• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

11.40 +0.35 (+3.17%)
Delayed Quote Updated: 11:27 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 310,880
Open 11.05
Bid (Size) 11.39 (100)
Ask (Size) 11.41 (400)
Prev. Close 11.05
Today's Range 11.05 - 11.43
52wk Range 9.390 - 16.29
Shares Outstanding 38,444,076
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
October 14, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript ↗
October 08, 2026
Medtech segment surges 13.2% as NanoKnife prostate procedures hit record volumes. 
Via The Motley Fool
Topics Earnings World Trade

Performance

52-Week Range 30.0% below 52-week high
11.40
9.3952W Low 16.2952W High
1 Week 17.4% below 1-week high
10.621W Low 13.801W High

AngioDynamics, Inc. - Common Stock (ANGO) traded between $9.39 and $16.29 over the past 52 weeks and last traded at $11.40, 30.0% below its 52-week high. Over the past week it ranged between $10.62 and $13.80.

Past 12 Months
+1.5%
-26.5%
-21.2%
+10.3%
-10.1%
-0.1%
1W +$0.17
1M -$4.11
3M -$3.07
6M +$1.06
YTD -$1.28
1Y -$0.01

ANGO was -0.1% over the past year, +10.3% over six months, -10.1% year to date, +1.5% in the last week.

12 Months vs Market
ANGO
-0.1%
DIA
+12.6%
SPY
+16.3%
QQQ
+21.2%
IWM
+10.5%

Over the past 12 months ANGO returned -0.1% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.3%, QQQ (Nasdaq 100) +21.2% and IWM (Russell 2000) +10.5%.

Volume & Liquidity 0.51× 3-mo avg
Today 310,880 3-mo avg 608.9K
1W
1.8M
1M
915.5K
3M
608.9K
6M
492.2K
YTD
519.1K
1Y
504.1K

ANGO most recently traded 310,880 shares against a 3-month average daily volume of 608.9K.

More News

Read More
News headline image
Why AngioDynamics Crashed Today ↗
October 08, 2026
Via The Motley Fool
AngioDynamics (NASDAQ:ANGO) Posts Narrower Q1 Loss, Holds Guidance Below Consensus ↗
October 08, 2026
Via Chartmill
AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth ↗
July 14, 2026
Via Chartmill
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance ↗
April 02, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Thursday's session. ↗
October 08, 2026
Via Chartmill
News headline image
AngioDynamics Q1 Earnings Call Highlights ↗
October 08, 2026
Via MarketBeat
Topics Earnings
News headline image
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
October 08, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
October 08, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
October 02, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
September 28, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 ↗
August 11, 2026
Via MarketBeat
News headline image
AngioDynamics to Participate in Upcoming Investor Conferences
July 28, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript ↗
July 21, 2026
Via The Motley Fool
Topics Earnings World Trade
News headline image
AngioDynamics Q4 Earnings Call Highlights ↗
July 14, 2026
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: AngioDynamics Q4 2026 Earnings Call ↗
July 14, 2026
Via Benzinga
Topics Earnings
News headline image
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
July 14, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
June 30, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
June 17, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
May 28, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
May 13, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
April 02, 2026
Via MarketMinute
Topics Economy Retirement
News headline image
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
April 02, 2026
From AngioDynamics, Inc.
Via Business Wire

Frequently Asked Questions

Is AngioDynamics, Inc. - Common Stock publicly traded?
Yes, AngioDynamics, Inc. - Common Stock is publicly traded.
What exchange does AngioDynamics, Inc. - Common Stock trade on?
AngioDynamics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AngioDynamics, Inc. - Common Stock?
The ticker symbol for AngioDynamics, Inc. - Common Stock is ANGO on the Nasdaq Stock Market
What is the current price of AngioDynamics, Inc. - Common Stock?
The current price of AngioDynamics, Inc. - Common Stock is 11.40
When was AngioDynamics, Inc. - Common Stock last traded?
The last trade of AngioDynamics, Inc. - Common Stock was at 10/15/26 11:27 AM ET
What is the market capitalization of AngioDynamics, Inc. - Common Stock?
The market capitalization of AngioDynamics, Inc. - Common Stock is 438.26M
How many shares of AngioDynamics, Inc. - Common Stock are outstanding?
AngioDynamics, Inc. - Common Stock has 438M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap